MiNK Therapeutics (NASDAQ:INKT) Raised to “Hold” at Wall Street Zen

MiNK Therapeutics (NASDAQ:INKT) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Other equities research analysts have also recently issued reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of MiNK Therapeutics in a report on Wednesday, October 8th. HC Wainwright raised shares of MiNK Therapeutics from a “neutral” rating to a “buy” rating and set a $35.00 price objective for the company in a research note on Friday, August 15th. Finally, Zacks Research upgraded shares of MiNK Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, October 20th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $35.00.

MiNK Therapeutics Stock Performance

Shares of NASDAQ:INKT opened at $11.50 on Friday. The firm’s 50 day simple moving average is $13.23 and its 200-day simple moving average is $13.19. MiNK Therapeutics has a one year low of $4.56 and a one year high of $76.00. The firm has a market cap of $53.94 million, a PE ratio of -3.80 and a beta of 0.35.

MiNK Therapeutics (NASDAQ:INKT) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.21. Equities research analysts predict that MiNK Therapeutics will post -2.75 EPS for the current fiscal year.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.